Kalderos uses the minimum necessary data to review the 340B discount. Specifically, Kalderos uses the prescription ID, national drug code (“NDC”), units, date of service, national provider identifier (“NPI”), 340B covered entity ID, and certain drug information from the entity’s historical drug purchasing data to analyze the discount. If necessary, manufacturers may define additional required fields for the purpose of fulfilling the financial transaction. This data is required in order to analyze whether the discounts are consistent with 340B Program rules and whether a prohibited duplicate discount scenario exists.